- Home
- ARQT vs DYN Comparison
ARQT vs DYN Comparison
Compare ARQT & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- DYN
- Stock Information
- Founded
- ARQT 2016
- DYN 1984
- Country
- ARQT United States
- DYN United States
- Employees
- ARQT N/A
- DYN N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- DYN Medicinal Chemicals and Botanical Products
- Sector
- ARQT Health Care
- DYN Health Care
- Exchange
- ARQT Nasdaq
- DYN Nasdaq
- Market Cap
- ARQT 1.7B
- DYN 1.4B
- IPO Year
- ARQT 2020
- DYN 2020
- Fundamental
- Price
- ARQT $13.82
- DYN $10.32
- Analyst Decision
- ARQT Strong Buy
- DYN Strong Buy
- Analyst Count
- ARQT 6
- DYN 14
- Target Price
- ARQT $18.80
- DYN $44.57
- AVG Volume (30 Days)
- ARQT 1.9M
- DYN 2.5M
- Earning Date
- ARQT 08-13-2025
- DYN 08-11-2025
- Dividend Yield
- ARQT N/A
- DYN N/A
- EPS Growth
- ARQT N/A
- DYN N/A
- EPS
- ARQT N/A
- DYN N/A
- Revenue
- ARQT $212,819,000.00
- DYN N/A
- Revenue This Year
- ARQT $61.15
- DYN N/A
- Revenue Next Year
- ARQT $37.98
- DYN N/A
- P/E Ratio
- ARQT N/A
- DYN N/A
- Revenue Growth
- ARQT 100.03
- DYN N/A
- 52 Week Low
- ARQT $7.86
- DYN $6.36
- 52 Week High
- ARQT $17.75
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- ARQT 50.73
- DYN 34.25
- Support Level
- ARQT $12.97
- DYN $10.56
- Resistance Level
- ARQT $13.84
- DYN $15.23
- Average True Range (ATR)
- ARQT 0.61
- DYN 1.01
- MACD
- ARQT 0.02
- DYN -0.47
- Stochastic Oscillator
- ARQT 51.64
- DYN 4.10
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.